FOS

Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
BioSpace
Tue, 11/3/20 - 09:29 pm
Jounce Therapeutics
vopratelimab
Santhera
vamorolone
Puldysa
Aurinia Pharmaceuticals
FOS